• CK Life Sciences posted a loss attributable to shareholders of HK$28.7 million, narrowing 81% for the six months ended June 30, 2026.
• Revenue rose 4.22% to HK$2.72 billion, while loss per share improved to 0.30 Hong Kong cents.
• R&D spending fell after the Polynoma disposal into Nasdaq-listed TransCode, with Polynoma and RNAZ expenses no longer consolidated in 1H 2026.
• Cash and time deposits totaled HK$535.7 million, while bank borrowings stood at HK$6.18 billion with a net debt-to-capital ratio of 58%.
• Dogwood reported encouraging Phase 2b interim data for Halneuron in chemotherapy-induced neuropathic pain; TransCode advanced TTX-MC138 into Phase 2a in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CK Life Sciences International (Holdings) Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260811-12280010), on August 11, 2026, and is solely responsible for the information contained therein.